Shan Liyun, Wang Xiaoyun, Li Yanli, Li Lidang, Wu Sufang, Xi Xiaowei, Yang Yongbin
Department of Obstetrics and Gynecology, Shanghai General Hospital of Nanjing Medical University, Shanghai, China.
Transl Cancer Res. 2022 Aug;11(8):2582-2590. doi: 10.21037/tcr-21-2700.
Protein-L-isoaspartate O-methyltransferase-1 (PCMT1) is a protein carboxyl methyltransferase enzyme, which has been found to play roles in cancers. However, no clinical information about the correlation between cervical cancer and PCMT1 expression has been reported.
We used immunohistochemistry (IHC) to characterize the protein level of PCMT1 in human cervical intraepithelial neoplasia and cervical cancer specimens. The mRNA expression profile of PCMT1 in cervical cancer was also analyzed by using Gene Expression Omnibus (GEO) databases. The prognostic value of PCMT1 in patients with cervical cancer was evaluated by using the Kaplan-Meier plotter. Gene set enrichment analysis (GSEA) was conducted by using The Cancer Genome Atlas (TCGA) cervical cancer dataset.
The protein level of PCMT1 was increased in cervical high-grade squamous intraepithelial lesion (HSIL) (7.40±0.42) and cervical cancer tissues (10.70±0.54), compared to normal cervix (5.00±0.86) and low-grade squamous intraepithelial lesion (LSIL) (6.22±0.57) (P<0.05). the immunoreactivity score (IRS) of PCMT1 was also higher in cervical cancer tissues than in paired adjacent non-cancerous cervical tissues (9.03±0.52 6.32±0.46) (P<0.05). High expression of PCMT1 was associated with decreased overall survival (OS) of patients with cervical cancer (P=0.0022). GSEA demonstrated that cervical cancer patients with high expression of PCMT1 were enriched in the various cancer-related signaling pathways.
These results suggest that PCMT1 might be a diagnostic and prognostic biomarker for cervical cancer, and further validation studies should be performed.
蛋白质-L-异天冬氨酸O-甲基转移酶-1（PCMT1）是一种蛋白质羧基甲基转移酶，已发现其在癌症中发挥作用。然而，尚未有关于宫颈癌与PCMT1表达之间相关性的临床信息报道。
我们采用免疫组织化学（IHC）方法来表征人宫颈上皮内瘤变和宫颈癌标本中PCMT1的蛋白水平。还通过使用基因表达综合数据库（GEO）分析了宫颈癌中PCMT1的mRNA表达谱。使用Kaplan-Meier绘图仪评估PCMT1在宫颈癌患者中的预后价值。利用癌症基因组图谱（TCGA）宫颈癌数据集进行基因集富集分析（GSEA）。
与正常宫颈组织（5.00±0.86）和低级别鳞状上皮内瘤变（LSIL）组织（6.22±0.57）相比，宫颈高级别鳞状上皮内瘤变（HSIL）组织（7.40±0.42）和宫颈癌组织（10.70±（此处原文有误，应为0.54））中PCMT1的蛋白水平升高（P<0.05）。宫颈癌组织中PCMT1的免疫反应性评分（IRS）也高于配对的相邻非癌宫颈组织（9.03±0.52对6.32±0.46）（P<0.05）。PCMT1高表达与宫颈癌患者总生存期（OS）降低相关（P=0.0022）。GSEA表明，PCMT1高表达的宫颈癌患者富集于各种癌症相关信号通路。
这些结果表明，PCMT1可能是宫颈癌的诊断和预后生物标志物，应进行进一步的验证研究。
